Weisan Pan

Weisan Pan

Auto-generated profile, based on publicly available information

Weisan Pan

Shenyang Pharmaceutical University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2012 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
DLDandan Liu
Dandan Liu
HXHeming Xu
Heming Xu
BTBaocheng Tian
Baocheng Tian
KYKun Yuan
Kun Yuan
HPhao pan
hao pan
WPWeisan Pan
Weisan Pan

20 May 2014 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SSShuangshuang Song
Shuangshuang Song
HQHuan Qi
Huan Qi
JXJingwen Xu
Jingwen Xu
PGPan Guo
Pan Guo
FCFen Chen
Fen Chen
WPWeisan Pan
Weisan Pan

24 October 2013 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SSShuangshuang Song
Shuangshuang Song
FCFen Chen
Fen Chen
HQHuan Qi
Huan Qi
FLFei Li
Fei Li
TXTiegang Xin
Tiegang Xin
WPWeisan Pan
Weisan Pan

1 March 2012 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
BTBaocheng Tian
Baocheng Tian
QLQiuhua Luo
Qiuhua Luo
SSShuangshuang Song
Shuangshuang Song
DLDandan Liu
Dandan Liu
HPhao pan
hao pan
WPWeisan Pan
Weisan Pan

1 October 2013 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
WPWeisan Pan
Weisan Pan
SMShilin Ma
Shilin Ma
FCFen Chen
Fen Chen
XYXiaohui Ye
Xiaohui Ye
YDYingjie Dong
Yingjie Dong
NZNaixian Zhang
Naixian Zhang
The purpose of this study was to develop a docetaxel microemulsion containing an anti-tumor synergistic ingredient (Brucea javanica oil) and to investigate the characteristics of the microemulsion. Brucea javanica oil contains oleic acid and linoleic acids that have been shown by animal and human studies to inhibit tumor formation. The microemulsion containing Brucea javanica oil, medium-chain triglyceride, soybean lecithin, Solutol®HS 15, PEG 400, and water was developed for docetaxel intravenous administration. A formulation with higher drug content, lower viscosity, and smaller particle size was developed. The droplet size distribution of the dispersed phase of the optimized microemulsion was 13.5 nm, determined using a dynamic light scattering technique. The small droplet size enabled the microemulsion droplets to escape from uptake and phagocytosis by the reticuloendothelial system and increased the circulation time of the drug. The zeta potential was -41.3 mV. The optimized microemulsion was pale yellow, transparent, and non-opalescent in appearance. The value of the combination index was 0.58, showing that there was a synergistic effect when docetaxel was combined with Brucea javanica oil. After a single intravenous infusion dose (10 mg/kg) in male Sprague Dawley rats, the area under the curve of the microemulsion was higher and the half-time was longer compared with that of docetaxel solution alone, and showed superior pharmacokinetic characteristics. These results indicate that this preparation of docetaxel in emulsion is likely to provide an excellent prospect for clinical tumor treatment.

10 October 2013 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SSShuangshuang Song
Shuangshuang Song
BTBaocheng Tian
Baocheng Tian
FCFen Chen
Fen Chen
WZWenji Zhang
Wenji Zhang
YPYusheng Pan
Yusheng Pan
WPWeisan Pan
Weisan Pan
Objective: The objectives of this study were, first, to develop a free-flowing and stable proniosome formulation for poorly water-soluble drugs such as vinpocetine; and second, to estimate its bioavailability as oral drug delivery system. Methods: The proniosomes consisting of span60, cholesterol, sorbitol and vinpocetine were prepared by a novel approach. After the proniosomes were contacted with water, the suspension of vinpocetine-loaded niosomes formed automatically. The proniosomes and reconstituted niosomes were evaluated for their physicochemical characteristics, in vitro drug dissolution and release, integrity and stability at different GI tract pH conditions, in situ single-pass intestinal perfusion and in vivo bioavailability. Results: The proniosome powder exhibited excellent flowability. The reconstituted niosomes with high drug entrapment efficiency (89.67 ± 3.28%) showed spherical morphology with smooth surface under transmission electron microscope (TEM). X-ray diffraction (XRD) indicated that the drug was in an amorphous or molecular state in proniosome powder. In vitro dissolution and release study, proniosomes did enhance the dissolution and release rate compared to vinpocetine suspension in phosphate buffer solution (pH 7.2). Proniosome-derived niosomes could keep their integrity and stability at different GI tract pH conditions. The in situ single-pass intestinal perfusion indicated that encapsulation of vinpocetine into niosomes could largely improved the absorption of vinpocetine. The AUC(0−∞) of F2 and F3 was about 4.0- and 4.9-fold higher than that of the vinpocetine suspension, respectively. The results demonstrated the proniosomes indeed remarkably enhanced the oral bioavailability of vinpocetine. Conclusion: This study suggested the potential of proniosomes as stable precursors for the immediate preparation of niosome carrier systems.